Correlation Between Oncopeptides and Diamyd Medical

Can any of the company-specific risk be diversified away by investing in both Oncopeptides and Diamyd Medical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oncopeptides and Diamyd Medical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oncopeptides AB and Diamyd Medical AB, you can compare the effects of market volatilities on Oncopeptides and Diamyd Medical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oncopeptides with a short position of Diamyd Medical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oncopeptides and Diamyd Medical.

Diversification Opportunities for Oncopeptides and Diamyd Medical

-0.22

Correlation Coefficient

Oncopeptides  Diamyd Medical

Very good diversification

The 3 months correlation between Oncopeptides and Diamyd is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Oncopeptides AB and Diamyd Medical AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Diamyd Medical AB and Oncopeptides is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oncopeptides AB are associated (or correlated) with Diamyd Medical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Diamyd Medical AB has no effect on the direction of Oncopeptides i.e., Oncopeptides and Diamyd Medical go up and down completely randomly.

Pair Corralation between Oncopeptides and Diamyd Medical

Assuming the 90 days trading horizon Oncopeptides AB is expected to generate 0.74 times more return on investment than Diamyd Medical. However, Oncopeptides AB is 1.35 times less risky than Diamyd Medical. It trades about -0.09 of its potential returns per unit of risk. Diamyd Medical AB is currently generating about -0.3 per unit of risk. If you would invest  175.00  in Oncopeptides AB on December 4, 2024 and sell it today you would lose (26.00) from holding Oncopeptides AB or give up 14.86% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Oncopeptides AB  vs.  Diamyd Medical AB

Oncopeptides AB

Risk-Adjusted Performance

Weak

Over the last 90 days Oncopeptides AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Oncopeptides is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

Diamyd Medical AB

Risk-Adjusted Performance

Very Weak

Over the last 90 days Diamyd Medical AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Oncopeptides and Diamyd Medical

The main advantage of trading using opposite Oncopeptides and Diamyd Medical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oncopeptides position performs unexpectedly, Diamyd Medical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Diamyd Medical will offset losses from the drop in Diamyd Medical's long position.

The idea behind Oncopeptides AB and Diamyd Medical AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.